Merrem
(Meropenem)ApprovedSmall molecule
Meropenem is an antibiotic used to treat serious bacterial infections, including infections of the brain, lungs, urinary tract, and bloodstream. It works by killing bacteria that cause these infections.[2] Merrem is currently approved and in use across 34 indications[4].[1]
Merrem is one of 530 small molecule programs targeting Acute Pancreatitis. It is currently in Approved.
34
Indications
109
Total Trials
9
Active Trials
529
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 33 indications
Competition
Competitive Landscape
152 competitors in Pneumonia
#DrugCompanyPhaseTrials
1Merrem
BB. Braun Medical Inc.
Approved
Jakafi
IncytePreclinical
Prevacid
TakedaPreclinical
Plaquenil
Jazz PharmaceuticalsPreclinical
Virazole
CConrado Roberto Hoffmann Filho
Preclinical
Advil
KKenvue Brands
Preclinical
Retrovir
BBp Consulting, Inc
Preclinical
Primsol
CConrado Roberto Hoffmann Filho
Preclinical
Pepcid
KKenvue Brands
Preclinical
Aciphex
Akero TherapeuticsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Meropenem11 trials
Show 8 more trials
Efficacy and Pharmacokinetics of Meropenem in Severe Septic Patients
Completed·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·Phase 4·NCT03645668·80 enrolled
Sepsis8 trials
Show 5 more trials
Urinary Tract Infection7 trials
Show 4 more trials
Complicated Intra-abdominal Infections6 trials
Show 3 more trials
Pneumonia4 trials
48 more indications
Antibiotics4 trials
Cystic Fibrosis4 trials
Neutropenia4 trials
Treatment3 trials
Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins
Completed·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 3·NCT04478721·334 enrolled
Septic Shock3 trials
Infections3 trials
Bloodstream Infection3 trials
Infection2 trials
Acute Pancreatitis2 trials
Comparing the Outcome in Patients of Acute Pancreatitis, With and Without Prophylactic Antibiotics
Completed·—·Phase 1/2·NCT02212392·90 enrolled
Ventilator-Associated Pneumonia2 trials
Antibiotic Therapy2 trials
Concentration2 trials
Intra-abdominal Infection2 trials
Typhoid Fever2 trials
Antibiotic1 trial
AbioKin - Antibiotic Kinetics
Completed·GGruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva··NCT02609646·1,500 enrolled
Cancer1 trial
Prospective1 trial
Efficacy and Safety1 trial
Ampicillin1 trial
CAR1 trial
Pulmonary Tuberculosis1 trial
Safety and Efficacy1 trial
Adult Subject1 trial
Randomized Controlled Trial1 trial
Intra-abdominal Infections1 trial
Meningitis1 trial
Efficacy1 trial
ART1 trial
Intensive Care Unit1 trial
Nosocomial Infection1 trial
Toxicity1 trial
Antidote for Valproic Acid Toxicity: a New Indication for Meropenem Antibiotic.
Unknown status·—·Phase 4·NCT04671589·48 enrolled
Enhanced Recovery After Surgery1 trial
Multicentral Preventive Antibiotics With Cystectomy Within Enhanced Recovery After Surgery
Unknown status·NN.N. Petrov National Medical Research Center of Oncology·Phase 3·NCT05392634·98 enrolled
Drug Resistance1 trial
Intensive Care1 trial
Complication1 trial
Randomized1 trial
Bacterial Pneumonia1 trial
Acute Kidney Injury1 trial
Regulatory
FDA Approval Timeline[5]
Jun 21, 1996
MERREM IV
NDA NDA050706
Apr 30, 2015
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER
NDA NDA202106
Jul 26, 2023
MEROPENEM
NDA NDA215212
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Merrem drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Meropenem. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Bacterial Penicillin-Binding Protein Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- BB. Braun Medical Inc.